Skip to main content
Premium Trial:

Request an Annual Quote

Sigma-Aldrich Licenses Polyplus-transfection's ZNA Technology

NEW YORK (GenomeWeb News) – Sigma-Aldrich said today that it will make and market oligonucleotides developed by Polyplus-transfection, a Strasbourg, France-based firm, under a new worldwide license agreement.

The agreement covers Polyplus-transfection's Zip Nucleic Acid (ZNA) oligonucleotides, which are designed for use in research and diagnostic applications.

ZNA oligonucleotides have attached cationic units that increase their sensitivity and ability to detect mutations. They are used in PCR probes and primers, siRNA, and in vitro micro RNA detection, Sigma-Aldrich said.

"The increased performances seen for ZNA oligonucleotides offer advantages for our customers, and we look forward to making this technology available to our global customer base," Sigma Custom Products VP Theresa Creasey said in a statement.

Financial terms of the agreement were not released.

The Scan

Single-Cell Sequencing Points to Embryo Mosaicism

Mosaicism may affect preimplantation genetic tests for aneuploidy, a single-cell sequencing-based analysis of almost three dozen embryos in PLOS Genetics finds.

Rett Syndrome Mouse Model Study Points to RNA Editing Possibilities

Investigators targeted MECP2 in mutant mouse models of Rett syndrome, showing in PNAS that they could restore its expression and dial down symptoms.

Investigators Find Shared, Distinct Genetic Contributors to Childhood Hodgkin Lymphoma

An association study in JAMA Network Open uncovers risk variants within and beyond the human leukocyte antigen locus.

Transcriptomic, Epigenetic Study Appears to Explain Anti-Viral Effects of TB Vaccine

Researchers report in Science Advances on an interferon signature and long-term shifts in monocyte cell DNA methylation in Bacille Calmette-Guérin-vaccinated infant samples.